Approximately half of breast cancers (BCs), historically categorized as human epidermal
growth factor receptor 2 (HER2)-negative, have low expression of HER2 defined as an …

Endocrine therapy (ET) is the cornerstone of management in hormone receptor (HR)+ breast
cancer (BC). Indeed, targeting the estrogen receptor (ER) signaling at different levels is a …

Opinion statement Breast cancer (BC) guidelines subdivide the disease into three main
groups, namely hormone receptor (HR)–positive HER2-negative, HER2-positive, and triple …

PURPOSE Determining the estrogen receptor (ER) status is essential in metastatic breast
cancer (MBC) management. Whole-body ER imaging with 16α-[18F] fluoro-17β-estradiol …

Background Artificial intelligence (AI) has the potential to personalize treatment strategies for
patients with cancer. However, current methodological weaknesses could limit clinical …

Molecular profiling guides precision treatment of breast cancer; however, Asian patients are
underrepresented in publicly available large-scale studies. We established a …

Improving the prognosis for patients with metastatic HR+/HER2-breast cancer remains an
unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not …

Breast cancer prognosis is steadily improving due to early detection of primary cancer in
screening programs and revolutionizing treatment development. In the metastatic setting …

ESR1 mutation (ESR1 m) is a frequent cause of acquired resistance to aromatase inhibitor
(AI) plus cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), which is a first-line therapy …

Metastasis represents the most important cause of breast cancer-associated mortality. Even
for early diagnosed stages, the risk of metastasis is significantly high and predicts a grim …